Aurobindo Pharma is planning to invest around Rs 1,300 crore towards capex during the ongoing and next financial years. The capex will be spread out across APIs (active pharmaceutical ingredients) and formulations and the company’s operations have resulted in substantial improvement to support the capex through internal cash generation.
Moreover, the pharma company spent around Rs 275 crore during the first half the current year. Meanwhile, consolidated net operating income of Aurobindo in second quarter of the ongoing fiscal grew 50 per cent to Rs 2,881 crore over the same period a year ago. Profit After Tax (after minority interest) was up by 58.4 per cent to Rs 372.2 crore during the July-September quarter against Rs 235 crore in the same quarter last fiscal.
No comments:
Post a Comment